<DOC>
	<DOC>NCT02989922</DOC>
	<brief_summary>This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and Overall Survival when compare with SOC.</brief_summary>
	<brief_title>A Study to Evaluate SHR-1210 in Subjects With Advanced HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Histologically confirmed HCC in advanced stage; not suitable to surgery or local regional treatment; with at least one measurable lesion per RECIST 1.1 2. Failed or intolerable to at least one prior systemic treatment for advanced HCC 3. ECOG Performance Status of 0 or1 4. ChildPugh Class A or B with 7 points 5. Life Expectancy of at least 12 weeks 6. HBV DNAï¼œ2000 IU/ml 7. Adequate organ function 8. Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug 1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 2. Known liver transplant or plan to transplant 3. GI hemorrhage with 6 months 4. Symptomatic brain metastases 5. Active known, or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>